Overview

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Status:
Active, not recruiting

Trial end date:
2023-12-15

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the efficacy and safety of WX-0593 in patients with ALK-positive NSCLC

Phase:

Phase 2

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.